Dhairya A. Patel

Array ( [id] => 20722367 [patent_doc_number] => 20260139070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-21 [patent_title] => Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies [patent_app_type] => utility [patent_app_number] => 19/449026 [patent_app_country] => US [patent_app_date] => 2026-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19449026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20568571 [patent_doc_number] => 20260062492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-05 [patent_title] => ANTIBODIES AGAINST TL1A AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/312502 [patent_app_country] => US [patent_app_date] => 2025-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 231 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19312502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20426592 [patent_doc_number] => 20250388679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-25 [patent_title] => SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/243836 [patent_app_country] => US [patent_app_date] => 2025-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26126 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19243836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19404923 [patent_doc_number] => 20240288434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers [patent_app_type] => utility [patent_app_number] => 18/629164 [patent_app_country] => US [patent_app_date] => 2024-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18629164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798964 [patent_doc_number] => 20250064889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR TREATING CANCERS [patent_app_type] => utility [patent_app_number] => 18/605112 [patent_app_country] => US [patent_app_date] => 2024-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18605112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19333658 [patent_doc_number] => 20240248088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => METHODS BASED ON THE DETECTION OF RAD51 FOCI IN TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 18/443660 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464224 [patent_doc_number] => 20240317893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => ANTI-DCLK1 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/427038 [patent_app_country] => US [patent_app_date] => 2024-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855565 [patent_doc_number] => 12258388 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Compositions and methods comprising SFRP2 antagonists [patent_app_type] => utility [patent_app_number] => 18/412245 [patent_app_country] => US [patent_app_date] => 2024-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 17 [patent_no_of_words] => 24759 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18412245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297517 [patent_doc_number] => 20240226082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => COMBINATION THERAPIES FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/541600 [patent_app_country] => US [patent_app_date] => 2023-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18541600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111319 [patent_doc_number] => 20240123069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => ANTIGEN RECOGNIZING RECEPTORS TARGETING UPAR AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/534969 [patent_app_country] => US [patent_app_date] => 2023-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33679 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 629 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18534969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097817 [patent_doc_number] => 20240117045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => TREATMENT OF HEAD AND NECK CANCER [patent_app_type] => utility [patent_app_number] => 18/491836 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971961 [patent_doc_number] => 20240052053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => ENHANCEMENT OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) [patent_app_type] => utility [patent_app_number] => 18/491464 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083161 [patent_doc_number] => 20240109962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => ANTIBODIES BINDING TO LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR SUBFAMILY B MEMBER 2 (LILRB2) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/476226 [patent_app_country] => US [patent_app_date] => 2023-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25367 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 290 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18476226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19004959 [patent_doc_number] => 20240069030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => NIDOGEN 1 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET OF HEPATOCELLULAR CARCINOMA, COMPOSITION AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 18/461081 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922999 [patent_doc_number] => 20240026003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/459842 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339325 [patent_doc_number] => 12049503 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Treatment of LAG-3 positive tumors [patent_app_type] => utility [patent_app_number] => 18/451990 [patent_app_country] => US [patent_app_date] => 2023-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 34 [patent_no_of_words] => 41325 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18451990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18901443 [patent_doc_number] => 20240016928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/363435 [patent_app_country] => US [patent_app_date] => 2023-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18363435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20555681 [patent_doc_number] => 20260055461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-26 [patent_title] => miR-25802 CLUSTER AS BIOMARKER FOR INFLAMMATION-ASSOCIATED DISEASE, AND USE OF miR-25802 CLUSTER [patent_app_type] => utility [patent_app_number] => 18/713459 [patent_app_country] => US [patent_app_date] => 2023-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18713459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19233795 [patent_doc_number] => 20240190987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => Engineered EpCam Binding Antibodies [patent_app_type] => utility [patent_app_number] => 18/349562 [patent_app_country] => US [patent_app_date] => 2023-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18349562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464197 [patent_doc_number] => 20240317866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer [patent_app_type] => utility [patent_app_number] => 18/216026 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18216026 [rel_patent_id] =>[rel_patent_doc_number] =>)